Email
Print
Menopausal Disorders Market - Forecast(2024 - 2030)
Menopausal Disorders Market Overview
Menopausal Disorders Market Size is estimated to reach $17.1 billion by 2027 and is poised to grow at a CAGR of 7.7% over the forecast period 2022-2027. Menopausal Disorders are disorders relating to having normal menstrual periods to no periods at all. During menopause, a woman's ovaries stop making eggs and produce less estrogen and progesterone. According to Johns Hopkins University, up to 80% of women would eventually suffer vasomotor symptoms like hot flashes, night sweats, anxiety and sleep difficulties; in severe cases, these can extend 10 years or more after the last menstrual period. About one-third of women would have practically unnoticeable symptoms. According to a Bayer report, by 2030, the world population of menopausal and postmenopausal women is projected to increase to 1.2 billion. Such a growing prevalence of menopausal disorders creates demand for various products and therapies to reduce the severity of menopausal symptoms and disorders. In June 2022, Astellas Pharma Inc announced a New Drug Application for fezolinetant that has been submitted to the USFDA. Thus, the high demand for menopausal treatment products drives the growth of the Menopausal Disorder Industry over the forecast period 2022-2027.
Menopausal Disorders Market Report Coverage
The report: “Menopausal Disorders Market Forecast
(2022-2027)" by Industry ARC, covers an in-depth analysis of the following
segments in the Menopausal Disorders Market.
By Treatment: Dietary
Supplement, OTC Pharma Products (Hormonal, Non-hormonal) and others.
By Stages: Menopause,
Pre-menopause and Post-menopause.
By End-users:
By Distribution Channel:
By Geography:
North America (the US, Canada and Mexico), Europe (Germany, the UK,
France, Italy, Spain, Russia and the Rest of Europe), Asia Pacific (China,
Japan India, South Korea, Australia and New Zealand and the Rest of Asia Pacific),
South America (Brazil, Argentina, Chile, Colombia and the Rest of South America)
and the Rest of the World (the Middle East and Africa).
Key Takeaways
- Geographically, North America held a dominant market share in the year 2021. The high spending capacity of women in this region surges the growth of the Menopausal Disorders Market Size.
- The Menopausal Disorders Market is predicted to increase, due to the growing population of women over the age of 50.
- However, the adverse effects of the medication may limit menopausal disorders industry growth over the forecast period.
- A detailed analysis of strengths, weaknesses, opportunities and threats would be provided in the Menopausal Disorders Market Report.
Menopausal Disorders Market: Market Share (%) by region, 2021
For more details on this report - Request for Sample
Menopausal Disorders Market Segment Analysis - By Treatment
Menopausal Disorders Market based on treatment can be further segmented into Dietary Supplement, OTC Pharma Products (Hormonal and Non-hormonal) and others. The Dietary Supplements segment held a dominant market share in the year 2021. This is due to the growing need for nutraceuticals to reduce menopausal symptoms such as hot flushes and others. In May 2022, a wellness brand O+ve, launched Meno, a supplement for women experiencing the effect of menopause. The growing demand for dietary supplements by women and innovative product launches by key market players drive the growth of the Menopausal Disorders Market Share. However, OTC Pharma products are estimated to grow with the fastest CAGR of 8.1% over the forecast period 2022-2027. The rise in demand for over-the-counter hormonal drug products to get relief from menopausal symptoms drive the growth. The most prevalent symptom of menopause is hot flashes which last for many years. Such a number of symptoms like hot flashes associated with sweats increase demand for OTC pharma products such as estrogen, fueling the growth of the Menopausal Disorders Market Share over the forecast period 2022-2027.
Menopausal Disorders Market Segment Analysis - By Distribution Channels
Menopausal Disorders Market based on the distribution channels can be further segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. The hospital pharmacy segment held a dominant market share in 2021. This is due to the growing number of hysterectomy or oophorectomy operations. According to Brigham and Women’s Hospital, approximately 6,00,000 hysterectomies are performed in the US every year. Such growing cases of hysterectomy or oophorectomy and growing hospitalization for such reasons drive demand for menopausal medication like hormonal or non-hormonal drugs such as estrogen. These factors also propel the growth of the Menopausal Disorders Market Share. However, Online Pharmacies are estimated to grow with the fastest CAGR of 9.6% over the forecast period 2022-2027. This is owing to the demand for various products to get relief from Menopausal symptoms such as hot flashes, night sweats and others.
Menopausal Disorders Market Segment Analysis - By Geography
North America held a dominant market share of 34% in 2021. This is due to the increasing number of women experiencing menopause in this region. According to the North American Menopause Society, approximately 6,000 women in the US reach menopause every day and around 2 million women per year. Such a growing number of menopausal women drives the Menopausal Disorders Market Size in this region. Furthermore, Asia-Pacific is estimated to grow with the fastest CAGR over the forecast period 2022-2027. This is because of the growing rate of the aging population and low awareness of menstrual health in this region. According to the World Development Report, the percentage of women over 50 in the total population of Asia-pacific was 8.20% in 1990 and it would be 17.08% in 2030. This factor would drive the growth of the Menopausal Disorders market size over the forecast period 2022-2027.
Menopausal Disorders Market Drivers
Increase in Income of Women:
With the growing urbanization and increasing share of women in employment, there is a noticeable growth in women’s income. According to Our World in Data, a 60.22% increase in women’s labor participation was recorded in Sub-saharan Africa, 59.04% in East Asia-pacific and 55.82% in North America in 2021. Such growing participation of women in the labor force increases their purchasing power in the area of wellness and fuels the growth of the Menopausal Disorders Industry over the forecast period 2022-2027.
The Raising Prevalence of Vasomotor and Menopausal Symptoms:
Menopause is a natural biological process, but its symptoms such
as irregular periods, vaginal dryness, hot flashes, night sweats and sleep
problems are experienced by nearly every woman in the world. The North American
Menopause Society (NAMS) estimates that over 23% of women experience mood
swings prior to, during and post-menopause. The rising prevalence of
menopausal symptoms surges demand for various products, to reduce the severity
of symptoms and drives the growth of the Menopausal Disorders Industry over the
forecast period 2022-2027.
Menopausal Disorders Market Challenge
Adverse Effect of Menopausal Medication & Therapy:
The side effects of treatments & drugs are the biggest obstacle in the global market for Menopausal Disorders. The Hormonal Replacement Therapy (HRT) used for the treatment of menopause is also associated with an increased risk of blood clots and certain types of cancer. According to the American Cancer Society, about 19,880 women would receive a new diagnosis of ovarian cancer and 12,810 women would die from ovarian cancer in 2022. This would hamper the Menopausal Disorders Industry growth over the forecast period 2022-2027.
Menopausal Disorders Market Industry Outlook
Product launches, mergers and acquisitions, joint ventures and
geographical expansions are key strategies adopted by players in the Menopausal
Disorders Market. The top 10 companies in the Menopausal Disorders Industry are:
- Hoffmann-La Roche Ltd.
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Sanofi S.A.
- Pfizer Inc.
- GlaxoSmithKline
- Novartis AG
- AstraZeneca
- Johnson & Johnson Private Limited
- Merck & Co., Inc.
Recent Developments
- In June 2022, Roche announced the launch of a human papillomavirus (HPV) self-sampling solution in countries accepting the CE mark. This new solution enables a patient to privately collect her sample for HPV screening while at a healthcare facility.
- In November 2021, Pfizer Inc and Biohaven Pharmaceutical Holding Company Ltd announced a strategic commercialization arrangement for rimegepant in markets outside of the United States upon approval.
- In July 2021, AstraZeneca announced the completion of the acquisition of Alexion Pharmaceuticals, Inc. With this acquisition, the company entered into medicines for rare diseases.
Relevant Titles
Women's
Health Ingredients Market - Industry Analysis, Market Size, Share, Trends,
Application Analysis, Growth and Forecast Analysis
Report Code: FBR 0269
Postmenopausal
Hormone Therapy Market - Industry Analysis, Market Size, Share, Trends,
Application Analysis, Growth and Forecast Analysis
Report Code: HCR 0629
Progesterone
Market - Industry Analysis, Market Size, Share, Trends, Application Analysis,
Growth and Forecast Analysis
Report Code:
For more Lifesciences and Healthcare related reports, please click here